Literature DB >> 25312536

Biliary and hepatic involvement in IgG4-related disease.

D Joshi1, G J M Webster.   

Abstract

BACKGROUND: IgG4-related disease (IgG4-RD) is a multi-systemic disorder. IgG4-related sclerosing cholangitis (IgG4-SC) is the biliary manifestation of the disease, often in association with autoimmune pancreatitis (AIP). Hepatic manifestations of IgG4-RD are less well described within the literature. AIM: To examine and present an overview of IgG4-RD with a focus on the biliary and hepatic manifestations.
METHODS: An electronic search using Medline was performed. Search items included 'IgG4 multi-system disease, IgG4 associated cholangitis, IgG4 associated liver disease and autoimmune pancreatitis (AIP)'.
RESULTS: IgG4-RD is characterised by an IgG4-positive lymphoplasmacytic tissue infiltrate, storiform fibrosis and an obliterative phlebitis. The HISORt criteria may be used to establish the diagnosis and incorporate a multi-disciplinary approach involving histology, radiology, serum IgG4 levels and response to steroid therapy. IgG4-SC is the commonest extrapancreatic manifestation of type-1 AIP, while the hepatic manifestations remain poorly defined. Important differential diagnoses include primary sclerosing cholangitis, secondary sclerosing cholangitis, cholangiocarcinoma and pancreatic carcinoma. Current treatment regimens remain ill defined although steroid therapy is used first line unless contraindicated. Patients with relapsing disease or multifocal disease should be considered for azathioprine. Available data would also suggest a role for rituximab.
CONCLUSIONS: IgG4-related sclerosing cholangitis is a common manifestation of IgG4-related disease which requires a multi-disciplinary approach to establish the diagnosis. Differentiating IgG4-related sclerosing cholangitis from other conditions, both benign and malignant, is challenging, but vital. Steroids remain the mainstay of treatment. Our understanding of the pathogenesis of the hepatic manifestations of IgG4-related disease continues to evolve.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25312536     DOI: 10.1111/apt.12988

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

Review 1.  Immunology of IgG4-related disease.

Authors:  E Della-Torre; M Lanzillotta; C Doglioni
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

Review 2.  Controversies in the management of primary sclerosing cholangitis.

Authors:  Jeremy S Nayagam; Stephen P Pereira; John Devlin; Phillip M Harrison; Deepak Joshi
Journal:  World J Hepatol       Date:  2016-02-18

Review 3.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

4.  IgG4-related disease with multiple organs involvement was effectively controlled by glucocorticoids: a case report.

Authors:  Shuo Wang; Xiangbo Xu; Zhaohui Bai; Fangfang Yi; Ran Wang; Xiaozhong Guo; Xingshun Qi
Journal:  AME Case Rep       Date:  2020-10-30

5.  Eosinophilic cholangitis is a potentially underdiagnosed etiology in indeterminate biliary stricture.

Authors:  Dirk Walter; Sylvia Hartmann; Eva Herrmann; Jan Peveling-Oberhag; Wolf O Bechstein; Stefan Zeuzem; Martin-Leo Hansmann; Mireen Friedrich-Rust; Jörg G Albert
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

6.  Difficulty in differentiating between IgG4-related hepatic inflammatory pseudotumor and intrahepatic cholangiocarcinoma.

Authors:  Ai Hamano; Reiko Yamada; Kazunari Kurata; Junya Tsuboi; Hiroyuki Inoue; Kyosuke Tanaka; Noriyuki Horiki; Yoshiyuki Takei
Journal:  Clin J Gastroenterol       Date:  2020-10-09

7.  Differences in Clinical Features and Diagnostic Strategies Between IgG4-Related Autoimmune Cholangitis and Cholangiocarcinoma.

Authors:  Ke Zhu; Jin Yang; Ying-Zhen Chen; Xue-Rong Zhang; Xian-Huan Yu; Jie Wang; Rui Zhang; Chao Liu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

8.  Immunoglobulin G4-associated autoimmune hepatitis with peripheral blood eosinophilia: a case report.

Authors:  Arunchai Chang; Cheep Charoenlap; Keerati Akarapatima; Attapon Rattanasupar; Varayu Prachayakul
Journal:  BMC Gastroenterol       Date:  2020-12-11       Impact factor: 3.067

Review 9.  Immunoglobulin G4-related sclerosing cholangitis.

Authors:  George Goodchild; Stephen P Pereira; George Webster
Journal:  Korean J Intern Med       Date:  2018-07-27       Impact factor: 2.884

10.  Hepatic actinomycosis with immunoglobulin G4-related liver disease: A case report.

Authors:  Joo Hyung Lee; Hyung Sun Kim; Ji Sub Kim; Dong Ki Lee; Jin Hong Lim
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.